Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 374

Sort by

Sort Order Select

Journal Articles

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Nichola Cooper, MD MRCP, Isabel Gorham, BS RN, Ann M. Lowe, MD, Robert P. Numerof, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 4800.

https://doi.org/10.1182/blood-2019-126544

Published: 2019

Journal Articles

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Blood (2019) 134 (Supplement_1): 463.

https://doi.org/10.1182/blood-2019-127811

Published: 2019

Journal Articles

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Lingzhi Yan, Zhi Yan, Jingjing Shang, Xiaolan Shi, Song Jin, Liqing Kang, Su Qu, Jin Zhou, Huizhu Kang, Ruju Wang, Ying Yao, Jing Wang, Weiqin Yao, Guanghua Chen, Lei Yu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 578.

https://doi.org/10.1182/blood-2019-129740

Published: 2019

Journal Articles

Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Very Severe Veno-Occlusive Disease after Unmanipulated Haploidentical HSCT with Post-Transplant Cyclophosphamide

Ignacio Gómez-Centurión, MD, Nieves Dorado, MD, Rebeca Bailén, MD, Miguel Echenagusia, MD, Arturo Alvarez, MD, Gillen Oarbeascoa, MD, Cristina Muñoz, Javier Anguita, MD PhD, Jose L. Diez-Martin, MD PhD, Mi Kwon, MD

Blood (2019) 134 (Supplement_1): 1981.

https://doi.org/10.1182/blood-2019-125828

Published: 2019

Journal Articles

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

Steven Le Gouill, MD PhD, Franck Morschhauser, MD, Kamal Bouabdallah, MD, Guillaume Cartron, Olivier Casasnovas, MD, Thomas Gastinne, MD, Patrice Chevallier, MD, Cédric Rossi, MD PhD, Emmanuelle Tchernonog, MD, Rory McCulloch, FRCPath, MRCP, MBBS, Charles Herbaux, MD, David Chiron, PhD, Mary Callanan, PhD, Simon Rule

Blood (2019) 134 (Supplement_1): 1530.

https://doi.org/10.1182/blood-2019-125681

Published: 2019

Journal Articles

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Anjali S. Advani, MD, Anna Moseley, M.S., Michaela Liedtke, MD, Margaret R O'Donnell, MD, Ibrahim Aldoss, MD, Martha P. Mims, MD PhD, Kristen Marie O'Dwyer, MD, Megan Othus, PhD, Harry P. Erba, MD PhD

Blood (2019) 134 (Supplement_1): 227.

https://doi.org/10.1182/blood-2019-125340

Published: 2019

Journal Articles

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

Jennifer R Brown, MD PhD, Kam Sprott, PhD, Santosh Reddy, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4312.

https://doi.org/10.1182/blood-2019-122491

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

James K McCloskey, MD, Joelle Gagnon, NP, Tara McCabe, FNP-C, MSN, RN, BSN, Jocelyn Charlon, MS, AGPCNP-BC, Shuqi Wang, MSc, Ruzong Fan, Stuart L. Goldberg, MD, Jamie Koprivnikar, MD

Blood (2019) 134 (Supplement_1): 3812.

https://doi.org/10.1182/blood-2019-131838

Published: 2019

Journal Articles

The Real-Life Data on the Outcome of Hepatitis B Infection in Patients with B-Cell Lymphoproliferative Neoplasms Treated with Ibrutinib

Abdulkadir Ercaliskan, MD, Ahmet Emre Eskazan, MD, Nurgul Ozgur Yurttas, MD, Selin Kucukyurt, MD, Ayse Salihoglu, MD, Dilek Keskin, MD, Deniz Ozmen, MD, Tugrul Elverdi, MD, Muhlis Cem Ar, MD PhD, Teoman Soysal, MD

Blood (2019) 134 (Supplement_1): 4316.

https://doi.org/10.1182/blood-2019-127794

Published: 2019

Journal Articles

Geranylgeranyl Diphosphate Synthase Inhibitor and Proteasome Inhibitor Combination Therapy in Multiple Myeloma

Staci L. Haney, PhD, Michelle L. Varney, MS, Lynette M. Smith, PhD, Sarah A. Holstein, MD PhD

Blood (2019) 134 (Supplement_1): 4417.

https://doi.org/10.1182/blood-2019-129244

Published: 2019

Journal Articles

Underdiagnosed Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party

Blood (2019) 134 (Supplement_1): 4483.

https://doi.org/10.1182/blood-2019-124065

Published: 2019

Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Blood (2019) 134 (Supplement_1): 494.

https://doi.org/10.1182/blood-2019-123674

Published: 2019

Journal Articles

Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events

Zahit Bolaman, Sehmus Ertop, Atakan Turgutkaya, Selim Cem, Ayse Hilal Eroglu Kucukerdiler, Birsen Sahip, Irfan Yavasoglu, MD

Blood (2019) 134 (Supplement_1): 5594.

https://doi.org/10.1182/blood-2019-131093

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Blood (2019) 134 (Supplement_1): 495.

https://doi.org/10.1182/blood-2019-130043

Published: 2019

Journal Articles

High Expression of BCAT1 promotes Acute Myeloid Leukemia Progression and Sensitize to PARP Inhibitor

Jie Jin, PhD, Jie Jin, PhD, Jiajia Pan, Yungui Wang, PhD, Shujuan Huang, Shihui Mao, Qing Ling, Jinghan Wang, MD PhD, Chenying Li

Blood (2019) 134 (Supplement_1): 5041.

https://doi.org/10.1182/blood-2019-125221

Published: 2019

Journal Articles

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Blood (2019) 134 (Supplement_1): 5473.

https://doi.org/10.1182/blood-2019-126588

Published: 2019

Journal Articles

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Blood (2019) 134 (Supplement_1): 2629.

https://doi.org/10.1182/blood-2019-122411

Published: 2019

Journal Articles

Veno-Occlusive Disease (VOD) after Hematopoietic Stem Cell Transplant (HSCR): Always a Catastrophic Illness?

Paolo Bernasconi, MD, Anna Amelia Colombo, MD, Daniela Caldera, MD, Oscar Borsani, MD

Blood (2019) 134 (Supplement_1): 5649.

https://doi.org/10.1182/blood-2019-125608

Published: 2019

Journal Articles

Safe Use of Hydroxyurea in Sickle Cell Disease Patients Hospitalized for Painful Vaso-Occlusive Episodes: Results of the Randomized, Open-Label Helps Study

Nicola Conran, PhD, Kleber Yotsumoto Fertrin, MD PhD, Claudia de Alvarenga Maximo, MD, Thais Oliveira, B.Sc., Clarisse Lobo, MD PhD, Fernando Ferreira Costa, MD PhD

Blood (2019) 134 (Supplement_1): 2303.

https://doi.org/10.1182/blood-2019-130106

Published: 2019

NARROW

Trial in Progress: Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Global Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Sequential CD19- and Bcma-Specific Chimeric Antigen Receptor T Cell Treatment for RRMM: Report from a Single Center Study

Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Very Severe Veno-Occlusive Disease after Unmanipulated Haploidentical HSCT with Post-Transplant Cyclophosphamide

Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

The Real-Life Data on the Outcome of Hepatitis B Infection in Patients with B-Cell Lymphoproliferative Neoplasms Treated with Ibrutinib

Geranylgeranyl Diphosphate Synthase Inhibitor and Proteasome Inhibitor Combination Therapy in Multiple Myeloma

Underdiagnosed Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome(VOD/SOS) As a Major Cause of Multi-Organ Failure in Acute Leukemia Transplant Patients: An Analysis from the EBMT Acute Leukemia Working Party

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events

High Expression of BCAT1 promotes Acute Myeloid Leukemia Progression and Sensitize to PARP Inhibitor

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Veno-Occlusive Disease (VOD) after Hematopoietic Stem Cell Transplant (HSCR): Always a Catastrophic Illness?

Safe Use of Hydroxyurea in Sickle Cell Disease Patients Hospitalized for Painful Vaso-Occlusive Episodes: Results of the Randomized, Open-Label Helps Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only